Influence of hypercapnia on the synthesis of neuropeptides and their receptors in murine brain

Respirology

Volumn 18, Issue 1, 2013, Pages 102-107

  Wang, Wei ^a   Li, Qingyi ^a   Pan, Yongchu ^a   Zhu, Donglin ^b   Wang, Lin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED BRAIN HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

galanin; hypercapnia; neuropeptide Y; obstructive sleep apnoea; orexin

Indexed keywords

BETA ACTIN; GALANIN; GALANIN RECEPTOR 2; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y RECEPTOR; OREXIN; OREXIN A;

AMBIENT AIR; ARTICLE; BRAIN; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; GENE EXPRESSION; HYPERCAPNIA; HYPOTHALAMUS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLEEP DISORDERED BREATHING; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN STEM; GALANIN; HYPERCAPNIA; HYPOTHALAMUS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; MICE, INBRED C57BL; NEUROPEPTIDE Y; NEUROPEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, NEUROPEPTIDE; SLEEP; SLEEP APNEA, OBSTRUCTIVE;

EID: 84871827863     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02245.x     Document Type: Article

References (51)

1. Mata Ruiz I, Ortiz Lobo A, Hernandex Monsalve M, et al,. [Insomnia in general practice: the opinion of the patient and the professional]. Aten. Primaria 1995; 16: 271-4.
2. Althuis MD, Fredman L, Langenberg PW, et al,. The relationship between insomnia and mortality among community-dwelling older women. J. Am. Geriatr. Soc. 1998; 46: 1270-3.
3. Haldemann R, Good M, Holsboer-Trachsler E,. [Epidemiological study of sleep disorders in patients in Swiss general practice]. Praxis (Bern 1994) 1996; 85: 1656-62.
4. Young T, Palta M, Dempsey J, et al,. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 1993; 328: 1230-5.
5. Saper CB, Chou TC, Scammell TE,. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001; 24: 726-31.
6. Dyzma M, Boudjeltia KZ, Faraut B, et al,. Neuropeptide Y and sleep. Sleep Med. Rev. 2010; 14: 161-5.
7. Mieda M, Hasegawa E, Kisanuki YY, et al,. Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. J. Neurosci. 2011; 31: 6518-26.
8. Wiater MF, Mukherjee S, Li AJ, et al,. Circadian integration of sleep-wake and feeding requires NPY receptor-expressing neurons in the mediobasal hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011; 301: R1569-83.
9. Karlsson RM, Holmes A,. Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease. Amino Acids 2006; 31: 231-9.
10. Williams RH, Jensen LT, Verkhratsky A, et al,. Control of hypothalamic orexin neurons by acid and CO2. Proc. Natl Acad. Sci. U.S.A. 2007; 104: 10685-90.
11. Sunanaga J, Deng BS, Zhang W, et al,. CO2 activates orexin-containing neurons in mice. Respir. Physiol. Neurobiol. 2009; 166: 184-6.
12. Kuwaki T,. Orexinergic modulation of breathing across vigilance states. Respir. Physiol. Neurobiol. 2008; 164: 204-12.
13. Abbott SB, Burke PG, Pilowsky PM,. Galanin microinjection into the PreBotzinger or the Botzinger Complex terminates central inspiratory activity and reduces responses to hypoxia and hypercapnia in rat. Respir. Physiol. Neurobiol. 2009; 167: 299-306.
14. Abbott SB, Pilowsky PM,. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009; 296: R1019-26.
15. Nishijima T, Sakurai S, Arihara Z, et al,. Plasma orexin-A-like immunoreactivity in patients with sleep apnea hypopnea syndrome. Peptides 2003; 24: 407-11.
16. Li NF, Yao XG, Zhu J, et al,. Higher levels of plasma TNF-alpha and neuropeptide Y in hypertensive patients with obstructive sleep apnea syndrome. Clin. Exp. Hypertens. 2010; 32: 54-60.
17. Goineau S, Rompion S, Guillaume P, et al,. Ventilatory function assessment in safety pharmacology: optimization of rodent studies using normocapnic or hypercapnic conditions. Toxicol. Appl. Pharmacol. 2010; 247: 191-7.
18. de Lecea L, Kilduff TS, Peyron C, et al,. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. U.S.A. 1998; 95: 322-7.
19. Sakurai T, Amemiya A, Ishii M, et al,. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-85.
20. Nakamura A, Zhang W, Yanagisawa M, et al,. Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J. Appl. Physiol. 2007; 102: 241-8.
21. Yoshida K, McCormack S, España RA, et al,. Afferents to the orexin neurons of the rat brain. J. Comp Neurol. 2006; 494: 845-61.
22. Terada J, Nakamura A, Zhang W, et al,. Ventilatory long-term facilitation in mice can be observed during both sleep and wake periods and depends on orexin. J. Appl. Physiol. 2008; 104: 499-507.
23. Zhu Y, Fenik P, Zhan G, et al,. Selective loss of catecholaminergic wake active neurons in a murine sleep apnea model. J. Neurosci. 2007; 27: 10060-71.
24. Kuwaki T,. Hypothalamic modulation of breathing. Adv. Exp. Med. Biol. 2010; 669: 243-7.
25. Sakurai S, Nishijima T, Takahashi S, et al,. Clinical significance of daytime plasma orexin-A-like immunoreactivity concentrations in patients with obstructive sleep apnea hypopnea syndrome. Respiration 2004; 71: 380-4.
26. Busquets X, Barbe F, Barcelo A, et al,. Decreased plasma levels of orexin-A in sleep apnea. Respiration 2004; 71: 575-9.
27. Aksu K, Firat Guven S, Aksu F, et al,. Obstructive sleep apnoea, cigarette smoking and plasma orexin-A in a sleep clinic cohort. J. Int. Med. Res. 2009; 37: 331-40.
28. Kiyashchenko LI, Mileykovskiy BY, Lai YY, et al,. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J. Neurophysiol. 2001; 85: 2008-16.
29. Peever JH, Lai YY, Siegel JM,. Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. J. Neurophysiol. 2003; 89: 2591-600.
30. Dutschmann M, Kron M, Morschel M, et al,. Activation of Orexin B receptors in the pontine Kolliker-Fuse nucleus modulates pre-inspiratory hypoglossal motor activity in rat. Respir. Physiol. Neurobiol. 2007; 159: 232-5.
31. Gestreau C, Bevengut M, Dutschmann M,. The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. Curr. Opin. Pulm. Med. 2008; 14: 512-18.
32. Sakurai T,. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 2007; 8: 171-81.
33. Hagan JJ, Leslie RA, Patel S, et al,. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl Acad. Sci. U.S.A. 1999; 96: 10911-16.
34. Bourgin P, Huitron-Resendiz S, Spier AD, et al,. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J. Neurosci. 2000; 20: 7760-5.
35. Huang ZL, Qu WM, Li WD, et al,. Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl Acad. Sci. U.S.A. 2001; 98: 9965-70.
36. Methippara MM, Alam MN, Szymusiak R, et al,. Effects of lateral preoptic area application of orexin-A on sleep-wakefulness. Neuroreport 2000; 11: 3423-6.
37. Xi MC, Morales FR, Chase MH,. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 2001; 901: 259-64.
38. Eggermann E, Serafin M, Bayer L, et al,. Orexins/hypocretins excite basal forebrain cholinergic neurones. Neuroscience 2001; 108: 177-81.
39. Scammell TE, Winrow CJ,. Orexin receptors: pharmacology and therapeutic opportunities. Annu. Rev. Pharmacol. Toxicol. 2011; 51: 243-66.
40. Toppila J, Stenberg D, Alanko L, et al,. REM sleep deprivation induces galanin gene expression in the rat brain. Neurosci. Lett. 1995; 183: 171-4.
41. Murck H, Held K, Ziegenbein M, et al,. Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG. Psychoneuroendocrinology 2004; 29: 1205-11.
42. Steiger A,. Neurochemical regulation of sleep. J. Psychiatr. Res. 2007; 41: 537-52.
43. Polotsky VY, Smaldone MC, Scharf MT, et al,. Impact of interrupted leptin pathways on ventilatory control. J. Appl. Physiol. 2004; 96: 991-8.
44. Pavia JM, Schioth HB, Morris MJ,. Role of MC4 receptors in the depressor and bradycardic effects of alpha-MSH in the nucleus tractus solitarii of the rat. Neuroreport 2003; 14: 703-7.
45. Haskell-Luevano C, Chen P, Li C, et al,. Characterization of the neuroanatomical distribution of agouti-related protein immunoreactivity in the rhesus monkey and the rat. Endocrinology 1999; 140: 1408-15.
46. Glass MJ, Chan J, Pickel VM,. Ultrastructural localization of neuropeptide Y Y1 receptors in the rat medial nucleus tractus solitarius: relationships with neuropeptide Y or catecholamine neurons. J. Neurosci. Res. 2002; 67: 753-65.
47. Stornetta RL, Akey PJ, Guyenet PG,. Location and electrophysiological characterization of rostral medullary adrenergic neurons that contain neuropeptide Y mRNA in rat medulla. J. Comp. Neurol. 1999; 415: 482-500.
48. Sharma SD, Raghuraman G, Lee MS, et al,. Intermittent hypoxia activates peptidylglycine alpha-amidating monooxygenase in rat brain stem via reactive oxygen species-mediated proteolytic processing. J. Appl. Physiol. 2009; 106: 12-19.
49. Antonijevic IA, Murck H, Bohlhalter S, et al,. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000; 39: 1474-81.
50. Fuxe K, Agnati LF, Harfstrand A, et al,. Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol. Scand. 1983; 118: 189-92.
51. Zini I, Merlo Pich E, Fuxe K, et al,. Actions of centrally administered neuropeptide Y on EEG activity in different rat strains and in different phases of their circadian cycle. Acta Physiol. Scand. 1984; 122: 71-7.